MedNous | Business of medical innovation

Evernow Publishing Ltd Privacy Policy. Read more.

Free featured article

AZ delivers growth in product sales

Country

United Kingdom

AstraZeneca Plc delivered a 4% increase in product sales in 2018 – the first annual increase since 2009 – prompting the company to declare a return to growth after years of patent expiries and efforts to rebuild its pharmaceutical pipeline.

Driving the increase were higher sales of the lung cancer drug Tagrisso, the diabetes medicine Farxiga and the antiplatelet Brilinta. In addition, the company generated more than $600 million each from Lynparza and Imfinzi, both new cancer medicines.

New Swiss company gains rights to CNS drug

Country

Switzerland

A venture capital syndicate led by Netherlands-based Life Sciences Partners (LSP) is providing $180 million to Arvelle Therapeutics GmbH, a recently created Swiss company, which has exclusive rights to develop and commercialise a new epilepsy drug in Europe.

Grey Wolf gets funding

Country

United Kingdom

Grey Wolf Therapeutics Ltd, an Oxford, UK based immuno-oncology company, has raised £10 million in a Series A financing round to advance new small molecule drugs for cancer. The financing was provided by Andera Partners (formerly Edmond de Rothschild Investment Partners) and Canaan Partners of the US.